Travis Alvin Thompson - 02 Jan 2025 Form 4 Insider Report for BICYCLE THERAPEUTICS PLC (BCYC)

Role
CHIEF ACCOUNTING OFFICER
Signature
/s/ Jason Minio, Attorney-in-Fact
Issuer symbol
BCYC
Transactions as of
02 Jan 2025
Net transactions value
-$67,293
Form type
4
Filing time
06 Jan 2025, 19:30:31 UTC
Previous filing
13 Nov 2024
Next filing
04 Apr 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BCYC Ordinary Shares Award $0 +17,500 +91% $0.000000 36,741 02 Jan 2025 Direct F1, F2
transaction BCYC Ordinary Shares Sale $24,658 -1,750 -4.8% $14.09 34,991 02 Jan 2025 Direct F3, F4
transaction BCYC Ordinary Shares Sale $2,345 -159 -0.45% $14.75 34,832 03 Jan 2025 Direct F3, F5
transaction BCYC Ordinary Shares Sale $40,290 -2,686 -7.7% $15.00 32,146 06 Jan 2025 Direct F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BCYC Employee Stock Option (right to buy) Award $0 +43,500 $0.000000 43,500 02 Jan 2025 Ordinary Shares 43,500 $14.00 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Represents a restricted stock unit ("RSU") award. One-fourth (1/4) of the total number of RSUs shall vest on January 2, 2026 and the remaining RSUs shall vest in 12 equal quarterly installments thereafter.
F2 Each RSU represents a contingent right to receive one ordinary share.
F3 Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.90 to $14.15 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) and (5).
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.69 to $14.75 inclusive.
F6 This transaction occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 13, 2024.
F7 This option shall vest with respect to one-fourth (1/4) of the total number of shares underlying the option on January 2, 2026 and the remaining shares in 36 equal monthly installments thereafter.